Urokinase-Derived Peptide A6
Ovarian Clear Cell Cystadenocarcinoma
Explore 2 assets in Ovarian Clear Cell Cystadenocarcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Gynecologic Oncology Group
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00939809CT.gov A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Clear Cell Cystadenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Urokinase-Derived Peptide A6 (this asset) | Gynecologic Oncology Group | P2 | B · 57 |
| Carboplatin | National Cancer Institute (NCI) | P2 | BB |
| Nivestim | University of Washington | P2 | B |
| Docetaxel | National Cancer Institute (NCI) | P2 | B |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | B |
| Nogitecan | Gynecologic Oncology Group | P2 | B |
| Metformin | University of Chicago | P2 | B |
| Sargramostim | University of Washington | P2 | B |
| Temsirolimus | National Cancer Institute (NCI) | P2 | B |
+15 more in the Ovarian Clear Cell Cystadenocarcinoma cohort
Other indications for Urokinase-Derived Peptide A6
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Endometrioid Adenocarcinoma | — | P2 | B · 57 |
| Ovarian Mucinous Cystadenocarcinoma | — | P2 | B · 57 |
| Ovarian Brenner Tumor | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Urokinase-Derived Peptide A6 in Ovarian Clear Cell Cystadenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/urokinase-derived-peptide-a6-ovarian-clear-cell-cystadenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →